Company profile for Turn Biotechnologies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a biotechnology company focused on restoring cells’ youthful vigor to repair damage caused by the aging process. Using a proprietary ERA™ Platform, we develop mRNA medicines that are specially formulated to instruct specific cells in the body to fight disease or repair damaged tissue. We do this by reprogramming the epigenome to restore cell function that people often lose as they age This approach can be used...
We are a biotechnology company focused on restoring cells’ youthful vigor to repair damage caused by the aging process. Using a proprietary ERA™ Platform, we develop mRNA medicines that are specially formulated to instruct specific cells in the body to fight disease or repair damaged tissue. We do this by reprogramming the epigenome to restore cell function that people often lose as they age This approach can be used to revitalize different cells throughout the body – we are researching its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis and ophthalmology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
319 North Bernardo Ave, Mountain View, California 94043
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/klotho-neurosciences-announces-expiration-of-letter-of-intent-302577628.html

PR NEWSWIRE BIO
07 Oct 2025

https://www.prnewswire.com/news-releases/klotho-neurosciences-signs-letter-of-intent-to-acquire-select-assets-from-turn-biotechnologies-anchored-by-300-million-global-pharma-partnership-302570344.html

PR NEWSWIRE
30 Sep 2025

https://www.prnewswire.com/news-releases/turn-biotechnologies-acquires-armms-vesicular-technology-to-increase-access-to-tissue-targets-for-its-epigenetic-reprogramming-therapies-302411491.html

PR NEWSWIRE
26 Mar 2025

https://www.prnewswire.com/news-releases/hanall-biopharma-signs-licensing-agreement-with-turn-biotechnologies-to-develop-novel-treatments-for-eye-and-ear-diseases-302156468.html

PR NEWSWIRE
28 May 2024

https://www.contractpharma.com/contents/view_breaking-news/2024-05-28/hanall-signs-exclusive-licensing-agreement-with-turn-biotechnologies/?widget=listSection

CONTRACT PHARMA
28 May 2024

https://www.prnewswire.com/news-releases/turn-biotechnologies-shows-promise-of-epigenetic-reprogramming-to-rejuvenate-skin-at-season-aesthetic-conference-301811888.html

PR NEWSWIRE
01 May 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty